Supplementary Figure S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression par Chuandong Geng (17315310)

Sujets:

Supplementary Figure S9 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression par Chuandong Geng (17315310)

Sujets:

Supplementary Figure S7 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression par Chuandong Geng (17315310)

Sujets:

Supplementary Table S4 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression par Chuandong Geng (17315310)

Sujets:

Supplementary Table S8 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression par Chuandong Geng (17315310)

Sujets:

Supplementary Dataset S2 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition par Cara Abecunas (14960274)

Sujets:

Supplementary Dataset S1 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition par Cara Abecunas (14960274)

Sujets:

Supplementary Dataset S4 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition par Cara Abecunas (14960274)

Sujets:

Supplementary Table S12 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression par Chuandong Geng (17315310)

Sujets:

Supplementary Dataset S6 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition par Cara Abecunas (14960274)

Sujets:

Supplementary Data S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML par Christopher T. Letson (16424095)

Sujets:

Supplementary Figure S14 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression par Chuandong Geng (17315310)

Sujets:

Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML par Christopher T. Letson (16424095)

Sujets:

Supplementary Figure S17 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression par Chuandong Geng (17315310)

Sujets:

Supplementary Figure S18 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression par Chuandong Geng (17315310)

Sujets:

Supplementary Table S9 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression par Chuandong Geng (17315310)

Sujets:

Supplementary Dataset S8 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition par Cara Abecunas (14960274)

Sujets:

Supplementary Figure S15 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression par Chuandong Geng (17315310)

Sujets:

Supplementary Figure S20 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression par Chuandong Geng (17315310)

Sujets:

Supplementary Table S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML par Christopher T. Letson (16424095)

Sujets: